Immatics N.V., a clinical-stage biopharmaceutical company, has announced the presentation of expanded data from its ongoing Phase 1b clinical trial evaluating the IMA203 PRAME cell therapy. The data, presented at the ASCO conference, indicate a continued median progression-free survival $(PFS)$ of ≥6 months in patients with advanced melanoma following the failure of checkpoint inhibition. This contrasts with the expected median PFS of 2-3 months in this patient population. The trial focuses on the therapeutic potential of IMA203, a PRAME-directed TCR T cell therapy, and aims to address the urgent need for new treatments in this area. Immatics is actively advancing the therapy through the ongoing Phase 3 SUPRAME trial, which is planned to be conducted in more than 50 sites across North America and Europe. Patient enrollment began in early 2025 and is anticipated to conclude in 2026, with a Biologics License Application submission to the FDA expected in the first quarter of 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.